Clinical Trial Update: Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) [Phase 3]

View source ↗

Summary

Phase 3 trial update for recombinant human B lymphocyte RC18 given subcutaneously in systemic lupus erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• RC18 (RC18)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED